Kopp

Thirteenth Floor Entertainment Group Brings Back the Screams For Their 2023 Season in Chicagoland

Retrieved on: 
Tuesday, September 5, 2023
Deadlands, Darkness, Infestation, Rob Zombie, Hampton House (Chicago), George Gibson (Commissary General), Joliet Correctional Center, History, Sale, Kopp, Commissary, News, Schiller Park, Nightclub, Fireworks, Chicago metropolitan area

CHICAGO, Sept. 5, 2023 /PRNewswire/ -- Thirteenth Floor Entertainment Group, the world's largest Halloween-themed entertainment company returns with its premier Halloween events in Chicagoland including the frightening Old Joliet Haunted Prison and the world-famous 13th Floor Haunted House Chicago, which features new and exciting attractions that bring guests behind the spookiness. Tickets for both attractions are on-sale starting mid-August, with prices starting at $19.99 on select nights.

Key Points: 
  • We will be introducing two new attractions brimming with horrifyingly innovative new scares and jaw-dropping sets," said Bryan Kopp, 13th Floor Chicago's General Manager.
  • "We look forward to celebrating a decade of screams and scares with you this Halloween."
  • 13th Floor Haunted House Chicago's 2023 side attractions will feature:
    *NEW* Behind The Screams: Gives attendees the ultimate behind-the-scenes tour of the 13th Floor Haunted House - lights on, no actors, wardrobe and makeup tour, history of the haunted house, and more!
  • For more information, visit 13thFloorChicago.com & HauntedPrison.com and follow 13th Floor Chicago and Old Joliet Haunted Prison on Instagram.

Chubb Appoints Edward Kopp to Lead Far East Region

Retrieved on: 
Thursday, August 17, 2023
Insurance, La Salle University, Hana Financial Group, Ed, Chubb Limited, HSBC Insurance (Asia Pacific), Cigna, Business administration, Three Mile Island accident health effects, Kopp, Region, Accident, Country, Property insurance, Management, Chubb, Far East

ZURICH, Aug. 17, 2023 /PRNewswire/ -- Chubb Limited today announced that Edward Kopp has been appointed Regional President, Far East.

Key Points: 
  • ZURICH, Aug. 17, 2023 /PRNewswire/ -- Chubb Limited today announced that Edward Kopp has been appointed Regional President, Far East.
  • Kopp will report to Juan Luis Ortega, Executive Vice President, Chubb Group and President, Overseas General Insurance, the company's general insurance operations in 51 countries and territories outside North America.
  • Kopp succeeds Diego Sosa who, as previously announced, was named Country President, Chubb Mexico and General Manager, Chubb Seguros Mexico.
  • Since joining Chubb in 2012, he also has served as Deputy Country President & Chief Operating Officer for Chubb in Korea and Country President for Chubb in Thailand.

History in the Making: TITLE Boxing Club Announces International Deal Across Nine Countries

Retrieved on: 
Thursday, November 17, 2022
Health, Washington State University, Boxing, University, Entrepreneurship, History, Kopp, Research, Multimedia, Life, Hotel, Publishing

SANTA MONICA, Calif., Nov. 17, 2022 /PRNewswire/ -- TITLE Boxing Club, the world's leading boxing fitness brand that offers a full-body, authentic heavy bag workout, has signed the brand's first international deal that will bring its presence to nine countries. As the largest deal in TITLE's history, the agreement puts the brand on the fast track to its development goal of having 300 clubs open by 2025.

Key Points: 
  • SANTA MONICA, Calif., Nov. 17, 2022 /PRNewswire/ -- TITLE Boxing Club , the world's leading boxing fitness brand that offers a full-body, authentic heavy bag workout, has signed the brand's first international deal that will bring its presence to nine countries.
  • "This international deal allows us to bring authentic boxing fitness to the masses," said Todd Wadler, CEO of TITLE Boxing Club and Co-Founder of BoxUnion.
  • As the leading authentic heavy bag boxing club, TITLE Boxing Club offers a workout designed to build your fitness, control your breathing, and clear your mind.
  • TITLE Boxing Club also allows consumers to workout anytime, anywhere through their digital subscription service, TITLE Boxing Club On Demand .

MDVIP Appoints Consumer Health Leader David Kopp to Board of Directors

Retrieved on: 
Wednesday, November 9, 2022
Organization, Physician, Growth, Patient, Yahoo!, Kopp, Fortis Healthcare, MDVIP, Internet, Harvard University, Healthline, Cardiovascular disease, 100 Best Workplaces in Europe, Health, Concierge medicine, WebMD, Marketing, Fortune, BOCA, Risk, Technology, CEO, Management, Health insurance, Health care, Facebook, The Walt Disney Company

BOCA RATON, Fla., Nov. 9, 2022 /PRNewswire/ -- MDVIP, the market leader in personalized healthcare with a network of 1,100 primary care physicians nationwide, today announced the appointment of David Kopp to its board of directors. Kopp, a veteran consumer health and digital media leader, most recently served as CEO of Healthline Media.

Key Points: 
  • BOCA RATON, Fla., Nov. 9, 2022 /PRNewswire/ -- MDVIP , the market leader in personalized healthcare with a network of 1,100 primary care physicians nationwide, today announced the appointment of David Kopp to its board of directors.
  • Kopp, a veteran consumer health and digital media leader, most recently served as CEO of Healthline Media.
  • Kopp is a seasoned chief executive in consumer health and digital media with expertise spanning strategy, product, marketing and technology.
  • In addition to MDVIP, Kopp serves as an advisor and director for a number of consumer healthcare organizations, including the non-profit Breastcancer.org.

Urovant Sciences Announces Publication of Pharmacokinetic Data on GEMTESA® (Vibegron 75mg) Administered as an Intact or Crushed Tablet

Retrieved on: 
Thursday, October 27, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Perception, Gesellschaft mit beschränkter Haftung, Medicine, Overactive bladder, Plasma, Liver, Breast milk, Instagram, Safety, 100 Best Workplaces in Europe, Vitamin, Taste, AES, Headache, AUC, Kopp, Adult, Orange County Business Journal, Drug development, I, Sex, Diarrhea, Digoxin, Neurogenic bladder dysfunction, FDA, Burden, Patient, Food additive, Urination, Food, Kidney, Urinary incontinence, Man, Science, Twitter, OAB, Urinary urgency, Vibegron, Nausea, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Sore throat, Urine, Urinary retention, Prevalence, NYSE, Upper respiratory tract infection, Nasal congestion, Urinary tract infection, Vats, Allergy, Dysphagia, Nocturia, Constipation, Public health, Pharmaceutical industry, Medical imaging, Perfume, Dietary supplement, Sexton, Cmax

In the study, which involved healthy adults, GEMTESA was administered in a single 75-mg dose as an intact tablet vs. crushed and mixed with applesauce.

Key Points: 
  • In the study, which involved healthy adults, GEMTESA was administered in a single 75-mg dose as an intact tablet vs. crushed and mixed with applesauce.
  • All patients received one treatment with intact tablet and one with crushed tablet, mixed with applesauce.
  • Additional reported TEAEs experienced by 2 participants were constipation (crushed, 13.3%; intact 6.7%) and nausea (crushed 6.7%, intact 0%) .
  • UROVANT, UROVANT SCIENCES, the UROVANT SCIENCES logo are trademarks of Urovant Sciences GmbH, registered in the U.S. and in other countries.

Urovant Sciences® Named 17th on the List of Fortune® Best Workplaces in BioPharma™ (2022)

Retrieved on: 
Wednesday, September 7, 2022
Clinical Trials, Human Resources, Biotechnology, Seniors, Other Science, Health, Research, Professional Services, Consumer, Publishing, Science, Nursing, Communications, Medical Supplies, Other Health, FDA, Practice Management, Physical Therapy, Managed Care, Pharmaceutical, Business, Medical Devices, Infectious Diseases, Hospitals, Fitness & Nutrition, People, Work, CEO, Man, Culture, Kopp, I, Upper respiratory tract infection, Organization, Urinary retention, Urinary urgency, Medicine, Urine, Overactive bladder, Twitter, Orange County Business Journal, Adult, Gesellschaft mit beschränkter Haftung, Nausea, Patient, Health, Sex, Great Places, Kidney, The Last Best Place, Vitamin, Headache, FDA, Nasal congestion, Diarrhea, Public health, Liver, LinkedIn, Multimedia, Instagram, Breast milk, 100 Best Workplaces in Europe, Sore throat, NYSE, Urinary tract infection, Vats, Achievement, Urinary incontinence, Urination, Allergy, Digoxin, Neurogenic bladder dysfunction, Nocturia, Burden, Feedback, Place, OAB, Health insurance, Management, Pharmaceutical industry, Risk management, Dietary supplement, Biopharma LLC, Sexton, Fortune, VideoRay UROVs

Great Place to Work and Fortune magazine have named Urovant Sciences as one of the 2022 Best Workplaces in BioPharma .

Key Points: 
  • Great Place to Work and Fortune magazine have named Urovant Sciences as one of the 2022 Best Workplaces in BioPharma .
  • Its an honor to be recognized by Fortune and Great Place to Work, said James Robinson, CEO of Urovant Sciences.
  • The Fortune Best Workplaces in BioPharma list is highly competitive.
  • UROVANT, UROVANT SCIENCES, the UROVANT SCIENCES logo and Powered by People and Possibilities are trademarks of Urovant Sciences GmbH, registered in the U.S. and in other countries.

Urovant Sciences® Presents Interim Data from Phase 2a Study of Investigational Novel Gene Therapy, URO-902, Supporting Safety, Tolerability, and Efficacy Endpoints at 2022 American Urological Association Meeting

Retrieved on: 
Friday, May 13, 2022
Health, Genetics, Clinical Trials, General Health, Pharmaceutical, Biotechnology, American Urological Association, Urination, Sex, Medicine, Urinary urgency, Urine, Sore throat, Overactive bladder, Vitamin, Neurogenic bladder dysfunction, Female, Nasal congestion, Urinary incontinence, Headache, Twitter, Science, Oakland University, Burden, Allergy, Nausea, Professor, Journal, Liver, Breast milk, Woman, Medical school, Beaumont, Vats, The Journal of Urology, Man, Urinary tract infection, Trial of the century, Diarrhea, NYSE, Department, Urinary retention, Catheter, Kopp, Digoxin, Doctor of Philosophy, I, Micturition syncope, Beaumont Hospital, Patient, OAB, Adult, FDA, Public health, LinkedIn, MD, Kidney, Upper respiratory tract infection, Population, Injection, Nocturia, Cystoscopy, Gesellschaft mit beschränkter Haftung, Safety, Pharmaceutical industry, Dietary supplement, Urology, Sexton

This was a prespecified, 12-week interim analysis of a 48-week multicenter, randomized, double-blind, placebo-controlled, dose-escalation study ( NCT04211831 ).

Key Points: 
  • This was a prespecified, 12-week interim analysis of a 48-week multicenter, randomized, double-blind, placebo-controlled, dose-escalation study ( NCT04211831 ).
  • Treatment-emergent adverse events occurred in 45.5% of patients receiving URO-902 24 mg, 46.2% receiving 48 mg, and 50.0% receiving placebo.
  • We are encouraged by these promising interim safety and efficacy findings for URO-902, said Sef Kurstjens, MD, PhD, Executive Vice President and Chief Medical Officer of Urovant Sciences.
  • UROVANT, UROVANT SCIENCES, the UROVANT SCIENCES logo, GEMTESA, and the GEMTESA logo are trademarks of Urovant Sciences GmbH, registered in the U.S. and in other countries.

Urovant Sciences to Present Interim Data from Phase 2a Study of Potential Novel Gene Therapy, URO-902, and New Analyses of Data from Phase 3 EMPOWUR Extension Trial of GEMTESA® (vibegron) 75 mg at 2022 American Urological Association Annual Meeting

Retrieved on: 
Wednesday, April 13, 2022
Health, Genetics, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Patient, Vitamin, Breast milk, Overactive bladder, Kidney, Urinary urgency, Urination, Medicine, Public health, Woman, Cystoscopy, I, Urinary tract infection, Twitter, Adult, Nasal congestion, Incidence, Neurogenic bladder dysfunction, Urinary retention, Sore throat, Burden, Digoxin, Kopp, LinkedIn, Injection, Vats, Urine, Nocturia, Allergy, Sex, Female, Liver, Urinary incontinence, Man, Headache, NYSE, Safety, FDA, OAB, Diarrhea, Nausea, Upper respiratory tract infection, Pharmaceutical industry, Medical imaging, Dietary supplement, Urology, Sexton

URO-902 has the potential to be the first gene therapy for patients with OAB.

Key Points: 
  • URO-902 has the potential to be the first gene therapy for patients with OAB.
  • If approved, this innovative treatment has the potential to address an unmet need for patients who have failed oral pharmacologic therapies.
  • Secondary endpoints were changes from EMPOWUR baseline at week 52 in average daily micturitions, UUI, urgency, and total urinary incontinence.
  • Sumitovant is a global biopharmaceutical company leveraging data-driven insights to rapidly accelerate development of new potential therapies for unmet patient conditions.

BlueWind Medical Ltd. Appoints Charles F. Cargile as Chief Financial Officer

Retrieved on: 
Tuesday, April 12, 2022
Urine, Company, IDE, Journal of Managed Care & Specialty Pharmacy, Urinary incontinence, American Urological Association, Marketing, United Kingdom, Chuck, Business, Board, Oklahoma State University–Stillwater, European Urology, PARK, OASIS, CFO, Mental health, Effectiveness, Overactive bladder, Kopp, Audit committee, Woman, CEO, Food, Newport Corporation, Director, OAB, Financial compensation, Regulation of tobacco by the U.S. Food and Drug Administration, Commercial software, Housing, Communities and Local Government Committee, FDA, University, Patient, Committee, Accounting, Management, Silviculture, Mirabegron, Man

PARK CITY, Utah, and HERZLIYA, Israel, April 12, 2022 /PRNewswire/ -- BlueWind Medical, Ltd., developer of the innovative RENOVA iStim™ implantable tibial neuromodulation (iTNM) device for treatment of Overactive Bladder, today announced the addition of Charles F. ("Chuck") Cargile to its leadership team as Chief Financial Officer.

Key Points: 
  • PARK CITY, Utah, and HERZLIYA, Israel, April 12, 2022 /PRNewswire/ -- BlueWind Medical, Ltd., developer of the innovative RENOVA iStim implantable tibial neuromodulation (iTNM) device for treatment of Overactive Bladder, today announced the addition of Charles F. ("Chuck") Cargile to its leadership team as Chief Financial Officer.
  • He will be a strong partner and an invaluable addition to the team," said Dan Lemaitre, Chairman and CEO of BlueWind Medical.
  • "With the potential for FDA marketing clearance in 2023, the addition of Chuck further prepares BlueWind Medical for commercialization and our next phase of corporate growth."
  • Mr. Cargile has more than 25 years of public company executive experience including 16 years as Chief Financial Officer of Newport Corporation from 2000 to 2016; 4 years as Chief Executive Officer and Chairman of the Board of Sunworks, Inc. from 2017 to 2021; and Chief Financial Officer of The Tattooed Chef from 2020 to 2021.

BlueWind Medical™ Ltd. Makes Key Additions to Leadership Team

Retrieved on: 
Thursday, January 6, 2022
United Kingdom, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Woman, University of California, Irvine Medical Center, Goal, M.B.A, Emerson University, Multan, PARK, Overactive bladder, European Urology, NHS, FDA, Human resources, Physical therapy, SVKM's NMIMS, Urine, R, University, Northwestern University, University of Northern Colorado, Kopp, Physician, Business, Mental health, American Urological Association, Communication, Food, Patient, Medtronic, CEO, IDE, HR, OAB, Industry, Roger W. Jones Award for Executive Leadership, Urinary incontinence, History of the National Health Service (England), National Health Service, St. Jude Medical, Kellogg School, Management, Pharmaceutical industry, Man, Guidant, Marketing

These new executive appointments will enhance our ability to build an effective and strategic team.

Key Points: 
  • These new executive appointments will enhance our ability to build an effective and strategic team.
  • Sandra Muhlfeld brings 20 years of experience commercializing new medical technologies in both early stage and large medical device companies.
  • Prior to joining Caldera Medical, Sandra held a variety of positions in global and U.S. marketing at Guidant and St. Jude Medical.
  • Lisa Mead brings over 30 years of Human Resources experience to BlueWind Medical including 20 years in the healthcare and medical device industry.